Belimumab After Rituximab in Resistant Primary Juvenile SS

The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome. Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS. Participants will: Recieve Rituximab each week for 2-4 times until B%\<0.5% or B#\<20×10\^6/L Recieve Belimumab 4 weeks after the last use of Rituximab, and then every 4 weeks until week 28

NCT Number	NCT06410833
Lead Sponsor	Peking Union Medical College Hospital Collaborators: Children's Hospital of Chongqing Medical University, Central South University, Shenzhen Children's Hospital, The First Hospital of Jilin University, Children's Hospital of The Capital Institute of Pediatrics, The Affiliated Hospital of Qingdao University, Children's Hospital of Nanjing Medical University, Children's Hospital of Fudan University, Shengjing Hospital, Shanghai Children's Hospital, Tianjin Children's Hospital
Conditions	Sjogren's Syndrome, Pediatric ALL
Enrollment	15 participants
Start Date	2024-03-09
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-05-16